These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37942878)

  • 41. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia.
    Boyapati A; Sinclair R
    Australas J Dermatol; 2013 Feb; 54(1):49-51. PubMed ID: 22686691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prescribing Habits for Androgenic Alopecia Among Dermatologists in Spain in 2017: A Cross-Sectional Study.
    Pindado-Ortega C; Saceda-Corralo D; Buendía-Castaño D; Fernández-González P; Moreno-Arrones ÓM; Fonda-Pascual P; Alegre-Sánchez A; Rodrigues-Barata AR; Vañó-Galván S
    Actas Dermosifiliogr (Engl Ed); 2018; 109(6):536-542. PubMed ID: 29656764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Finasteride-associated male infertility.
    Chiba K; Yamaguchi K; Li F; Ando M; Fujisawa M
    Fertil Steril; 2011 Apr; 95(5):1786.e9-11. PubMed ID: 21193189
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Finasteride 1 mg in alopecia: sexual dysfunction, suicidal ideation. Providing balanced information to male patients is key.
    Prescrire Int; 2016 Oct; 25(175):242. PubMed ID: 30688421
    [No Abstract]   [Full Text] [Related]  

  • 45. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.
    Gupta AK; Charrette A
    J Dermatolog Treat; 2014 Apr; 25(2):156-61. PubMed ID: 23768246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the therapeutic effects of AGA drugs by measuring finasteride, dutasteride, and dihydrotestosterone in hair.
    Hobo Y; Nishikawa J; Taniguchi Asai N; Yoneyama K; Watanabe Y; Miyashiro Y; Fujikata A
    Clin Chim Acta; 2023 Jul; 547():117456. PubMed ID: 37385468
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia.
    Boersma IH; Oranje AP; Grimalt R; Iorizzo M; Piraccini BM; Verdonschot EH
    Indian J Dermatol Venereol Leprol; 2014; 80(6):521-5. PubMed ID: 25382509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A serious side effect of a potentially widely used cosmetic product.
    Smith VM; Cockshoot D
    Clin Exp Dermatol; 2015 Apr; 40(3):347-8. PubMed ID: 25622515
    [No Abstract]   [Full Text] [Related]  

  • 49. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis.
    Zhou Z; Song S; Gao Z; Wu J; Ma J; Cui Y
    Clin Interv Aging; 2019; 14():399-406. PubMed ID: 30863034
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Guidelines on the use of finasteride in androgenetic alopecia.
    Mysore V; Shashikumar BM
    Indian J Dermatol Venereol Leprol; 2016; 82(2):128-34. PubMed ID: 26924401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
    Belknap SM; Aslam I; Kiguradze T; Temps WH; Yarnold PR; Cashy J; Brannigan RE; Micali G; Nardone B; West DP
    JAMA Dermatol; 2015 Jun; 151(6):600-6. PubMed ID: 25830296
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
    Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
    BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology.
    Melcangi RC; Caruso D; Abbiati F; Giatti S; Calabrese D; Piazza F; Cavaletti G
    J Sex Med; 2013 Oct; 10(10):2598-603. PubMed ID: 23890183
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 'Post-finasteride syndrome': what to tell our female patients?
    Mervis JS; Borda LJ; Miteva M
    Br J Dermatol; 2018 Sep; 179(3):785-786. PubMed ID: 29624646
    [No Abstract]   [Full Text] [Related]  

  • 55. [Finasteride adverse effects: An update].
    Carreño-Orellana N; Moll-Manzur C; Carrasco-Zuber JE; Álvarez-Véliz S; Berroeta-Mauriziano D; Porras-Kusmanic N
    Rev Med Chil; 2016 Dec; 144(12):1584-1590. PubMed ID: 28393993
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of 5α-Reductase Inhibitor Use on Mortality From Prostate Cancer.
    Figg WD; Thompson IM
    JAMA Oncol; 2015 Jun; 1(3):321-2. PubMed ID: 26181178
    [No Abstract]   [Full Text] [Related]  

  • 57. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
    Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
    Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 5α-Reductase inhibitors in androgenetic alopecia.
    Yim E; Nole KL; Tosti A
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):493-8. PubMed ID: 25268732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of Postoperative Finasteride Therapy on Recurrence of Gynecomastia After Mastectomy in Men Taking Finasteride for Alopecia.
    Lee SG; Park PJ; Lee SR; Koo BH; Byun GY; Kim MJ; Kang HJ; Kim S; Oh BS; Lee YH
    Am J Mens Health; 2019; 13(5):1557988319871423. PubMed ID: 31552775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Finasteride in the treatment of female pattern (androgenic) alopecia: a case report and review of the literature.
    Boychenko O; Bernstein RM; Schweiger ES
    Cutis; 2012 Aug; 90(2):73-6. PubMed ID: 22988650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.